GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Femasys Inc (NAS:FEMY) » Definitions » ROE % Adjusted to Book Value

FEMY (Femasys) ROE % Adjusted to Book Value : -60.85% (As of Sep. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Femasys ROE % Adjusted to Book Value?

Femasys's ROE % for the quarter that ended in Sep. 2024 was -251.29%. Femasys's PB Ratio for the quarter that ended in Sep. 2024 was 4.13. Femasys's ROE % Adjusted to Book Value for the quarter that ended in Sep. 2024 was -60.85%.


Femasys ROE % Adjusted to Book Value Historical Data

The historical data trend for Femasys's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Femasys ROE % Adjusted to Book Value Chart

Femasys Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
ROE % Adjusted to Book Value
- - - -78.30 -73.75

Femasys Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -30.07 -106.53 -38.55 -62.02 -60.85

Competitive Comparison of Femasys's ROE % Adjusted to Book Value

For the Medical Instruments & Supplies subindustry, Femasys's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Femasys's ROE % Adjusted to Book Value Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Femasys's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Femasys's ROE % Adjusted to Book Value falls into.



Femasys ROE % Adjusted to Book Value Calculation

Femasys's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2023 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-84.81% / 1.15
=-73.75%

Femasys's ROE % Adjusted to Book Value for the quarter that ended in Sep. 2024 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-251.29% / 4.13
=-60.85%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Femasys ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of Femasys's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Femasys Business Description

Traded in Other Exchanges
N/A
Address
3950 Johns Creek Court, Suite 100, Suwanee, GA, USA, 30024
Femasys Inc is a biomedical company focused on transforming women's healthcare by developing solutions and advancements providing clinical impact to address severely underserved areas. The company's mission is to provide women with minimally invasive, non-surgical product technologies, accessible in the office, improving patient care and overall health economics.
Executives
Keith J Kendall director 30 TECHNOLOGY DRIVE, WARREN NJ 07059
Alistair Milnes director C/O BICYCLE THERAPEUTICS PLC, B900, BABRAHAM RESEARCH CAMPUS, CAMBRIDGE X0 CB22 3AT
Christine E Thomas officer: SVP, Regulatory & Clinical 2836 SW 117TH STREET, GAINESVILLE FL 32606
Dov Elefant officer: Chief Financial Officer EPICEPT CORPORATION, 270 SYLVAN AVENUE, ENGLEWOOD CLIFFS NJ 07632
Wendy Perrow director C/O BIOANALYTICAL SYSTEMS, INC., 2701 KENT AVENUE, WEST LAFAYETTE IN 47906
Edward Evantash officer: Chief Medical Officer 3950 JOHNS CREEK COURT, SUITE 100, SUWANEE GA 30024
John Dyett director, 10 percent owner 11111 SANTA MONICA BLVD., SUITE 2250, LOS ANGELES CA 90025
Adams John Q Jr director 35 WYCK HILL LANE, WESTLAKE TX 76262
Edward R Uzialko director, 10 percent owner 4605 DUDLEY LANE, ATLANTA GA 30327
Charles Larsen director 28 SANDPIPER ROAD, TAMPA FL 33609
Kathy Lee-sepsick director, officer: Chief Executive Officer 3950 JOHNS CREEK COURT, SUITE 100, SUWANEE GA 30024
Daniel Scott Currie officer: Senior VP, Operations 3950 JOHNS CREEK COURT, SUITE 100, SUWANEE GA 30024
Kelley Hoskin Violet Alexandria officer: VP, Clinical & Medical Affairs 3950 JOHNS CREEK COURT, SUITE 100, SUWANEE GA 30024
Gary Thompson director 3950 JOHNS CREEK COURT, SUITE 100, SUWANEE GA 30024
William Benson Witte director 11111 SANTA MONICA BLVD., SUITE 2250, LOS ANGELES CA 90025

Femasys Headlines

From GuruFocus